DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,755 filers reported holding DANAHER CORPORATION in Q1 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $16,627,400 | +88.1% | 69,644 | +96.9% | 0.13% | -12.4% |
| Q1 2023 | $8,838,018 | -16.3% | 35,377 | -10.3% | 0.15% | -15.5% |
| Q4 2022 | $10,562,781 | -8.9% | 39,435 | -10.9% | 0.18% | -11.3% |
| Q3 2022 | $11,593,000 | +26.1% | 44,245 | +21.1% | 0.20% | +29.9% |
| Q2 2022 | $9,195,000 | -25.7% | 36,545 | -14.0% | 0.16% | -14.7% |
| Q1 2022 | $12,383,000 | +18.1% | 42,502 | +33.5% | 0.18% | +7.6% |
| Q4 2021 | $10,486,000 | +24.6% | 31,831 | +15.2% | 0.17% | +23.9% |
| Q3 2021 | $8,413,000 | -43.3% | 27,621 | -50.0% | 0.14% | -27.4% |
| Q2 2021 | $14,834,000 | +82.5% | 55,242 | +53.0% | 0.19% | -16.3% |
| Q1 2021 | $8,127,000 | +1751.3% | 36,107 | +1670.0% | 0.23% | +931.8% |
| Q3 2020 | $439,000 | +21.6% | 2,040 | 0.0% | 0.02% | 0.0% |
| Q2 2020 | $361,000 | +28.0% | 2,040 | 0.0% | 0.02% | +4.8% |
| Q1 2020 | $282,000 | -9.9% | 2,040 | 0.0% | 0.02% | -8.7% |
| Q4 2019 | $313,000 | -1.3% | 2,040 | -7.3% | 0.02% | 0.0% |
| Q3 2019 | $317,000 | +1.6% | 2,200 | 0.0% | 0.02% | +9.5% |
| Q2 2019 | $312,000 | +9.1% | 2,200 | 0.0% | 0.02% | +31.2% |
| Q1 2019 | $286,000 | – | 2,200 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |